vs
Stellar Bancorp, Inc.（STEL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Stellar Bancorp, Inc.的1.2倍（$127.1M vs $108.9M），再鼎医药同比增速更快（17.1% vs 0.8%），Stellar Bancorp, Inc.自由现金流更多（$92.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.2%）
Stellar Bancorp, Inc.是总部位于美国的金融控股公司，通过旗下全资银行子公司开展运营，提供全品类零售及商业银行服务，覆盖存款产品、个人及商业贷款、抵押贷款、财富管理解决方案，服务客群包括个人消费者、小微企业及区域企业客户。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
STEL vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$108.9M
营收增速更快
ZLAB
高出16.3%
0.8%
自由现金流更多
STEL
多$119.3M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $108.9M | $127.1M |
| 净利润 | $26.1M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 29.0% | -54.6% |
| 净利率 | 24.0% | — |
| 营收同比 | 0.8% | 17.1% |
| 净利润同比 | 3.7% | — |
| 每股收益（稀释后） | $0.52 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STELZLAB
| Q4 25 | $108.9M | $127.1M | ||
| Q3 25 | $105.6M | $115.4M | ||
| Q2 25 | $104.1M | $109.1M | ||
| Q1 25 | $104.8M | $105.7M | ||
| Q4 24 | $108.0M | $108.5M | ||
| Q3 24 | $107.8M | $101.8M | ||
| Q2 24 | $106.8M | $100.1M | ||
| Q1 24 | $108.4M | $87.1M |
净利润STELZLAB
| Q4 25 | $26.1M | — | ||
| Q3 25 | $25.7M | $-36.0M | ||
| Q2 25 | $26.4M | $-40.7M | ||
| Q1 25 | $24.7M | $-48.4M | ||
| Q4 24 | $25.2M | — | ||
| Q3 24 | $33.9M | $-41.7M | ||
| Q2 24 | $29.8M | $-80.3M | ||
| Q1 24 | $26.1M | $-53.5M |
毛利率STELZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率STELZLAB
| Q4 25 | 29.0% | -54.6% | ||
| Q3 25 | 30.5% | -42.3% | ||
| Q2 25 | 31.7% | -50.3% | ||
| Q1 25 | 29.6% | -53.3% | ||
| Q4 24 | 29.4% | -62.6% | ||
| Q3 24 | 39.6% | -66.6% | ||
| Q2 24 | 35.1% | -76.0% | ||
| Q1 24 | 30.4% | -80.7% |
净利率STELZLAB
| Q4 25 | 24.0% | — | ||
| Q3 25 | 24.3% | -31.2% | ||
| Q2 25 | 25.3% | -37.3% | ||
| Q1 25 | 23.6% | -45.8% | ||
| Q4 24 | 23.3% | — | ||
| Q3 24 | 31.4% | -40.9% | ||
| Q2 24 | 27.9% | -80.2% | ||
| Q1 24 | 24.1% | -61.4% |
每股收益（稀释后）STELZLAB
| Q4 25 | $0.52 | $-0.05 | ||
| Q3 25 | $0.50 | $-0.03 | ||
| Q2 25 | $0.51 | $-0.04 | ||
| Q1 25 | $0.46 | $-0.04 | ||
| Q4 24 | $0.47 | $-0.09 | ||
| Q3 24 | $0.63 | $-0.04 | ||
| Q2 24 | $0.56 | $-0.08 | ||
| Q1 24 | $0.49 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $419.5M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $715.5M |
| 总资产 | $10.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资STELZLAB
| Q4 25 | $419.5M | $689.6M | ||
| Q3 25 | $728.4M | $717.2M | ||
| Q2 25 | $578.1M | $732.2M | ||
| Q1 25 | $560.6M | $757.3M | ||
| Q4 24 | $911.2M | $779.7M | ||
| Q3 24 | $516.2M | $616.1M | ||
| Q2 24 | $490.3M | $630.0M | ||
| Q1 24 | $399.7M | $650.8M |
股东权益STELZLAB
| Q4 25 | $1.7B | $715.5M | ||
| Q3 25 | $1.7B | $759.9M | ||
| Q2 25 | $1.6B | $791.7M | ||
| Q1 25 | $1.6B | $810.8M | ||
| Q4 24 | $1.6B | $840.9M | ||
| Q3 24 | $1.6B | $667.7M | ||
| Q2 24 | $1.6B | $704.2M | ||
| Q1 24 | $1.5B | $762.2M |
总资产STELZLAB
| Q4 25 | $10.8B | $1.2B | ||
| Q3 25 | $10.6B | $1.2B | ||
| Q2 25 | $10.5B | $1.2B | ||
| Q1 25 | $10.4B | $1.2B | ||
| Q4 24 | $10.9B | $1.2B | ||
| Q3 24 | $10.6B | $985.3M | ||
| Q2 24 | $10.7B | $987.4M | ||
| Q1 24 | $10.7B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $92.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | 85.0% | -21.0% |
| 资本支出强度资本支出/营收 | 4.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.71× | — |
| 过去12个月自由现金流最近4个季度 | $173.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流STELZLAB
| Q4 25 | $97.0M | $-26.0M | ||
| Q3 25 | $63.6M | $-32.0M | ||
| Q2 25 | $25.8M | $-31.0M | ||
| Q1 25 | $-5.7M | $-61.7M | ||
| Q4 24 | $132.6M | $-55.8M | ||
| Q3 24 | $59.5M | $-26.8M | ||
| Q2 24 | $38.1M | $-42.2M | ||
| Q1 24 | $31.1M | $-90.1M |
自由现金流STELZLAB
| Q4 25 | $92.6M | $-26.7M | ||
| Q3 25 | $62.5M | $-35.0M | ||
| Q2 25 | $24.5M | $-33.9M | ||
| Q1 25 | $-6.4M | $-63.2M | ||
| Q4 24 | $128.0M | $-58.4M | ||
| Q3 24 | $57.7M | $-28.2M | ||
| Q2 24 | $37.1M | $-42.9M | ||
| Q1 24 | $30.5M | $-91.1M |
自由现金流率STELZLAB
| Q4 25 | 85.0% | -21.0% | ||
| Q3 25 | 59.2% | -30.4% | ||
| Q2 25 | 23.6% | -31.1% | ||
| Q1 25 | -6.2% | -59.9% | ||
| Q4 24 | 118.5% | -53.8% | ||
| Q3 24 | 53.5% | -27.7% | ||
| Q2 24 | 34.8% | -42.9% | ||
| Q1 24 | 28.2% | -104.5% |
资本支出强度STELZLAB
| Q4 25 | 4.0% | 0.5% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 0.7% | 1.5% | ||
| Q4 24 | 4.3% | 2.4% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 0.9% | 0.7% | ||
| Q1 24 | 0.5% | 1.1% |
现金转化率STELZLAB
| Q4 25 | 3.71× | — | ||
| Q3 25 | 2.48× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | -0.23× | — | ||
| Q4 24 | 5.26× | — | ||
| Q3 24 | 1.76× | — | ||
| Q2 24 | 1.28× | — | ||
| Q1 24 | 1.19× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STEL
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
